Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Asia On The Move: People News From GSK, Eisai And Others

This article was originally published in PharmAsia News

Executive Summary

GSK’s Japan subsidiary appoints a new executive director; Eisai has a new general manager for China; WuXi appoints an independent board director for audit; and Chugai enhances compliance governance.

You may also be interested in...



China 'No' For Celgene's Paclitaxel A Major Blow To BeiGene

After winning a major procurement contract, BeiGene now may need to find an alternative manufacturing site for  Celgene's Abraxane to supply China.

Coronavirus Clash: Global Pharma Scrambles In Locking Down World

A former pharma executive shares views with Scrip about the coronavirus in China, the challenges facing corporations and individuals in a rapidly changing world and coming threats that could potentially cause even more damage than the pandemic.

China Clears First Coronavirus Vaccine Trial

Leveraging its Ebola vaccine success, Tianjin-based CanSino is looking to launch China’s first vaccine for COVID-19 as it secures permission to start local clinical trials.

Topics

Related Companies

UsernamePublicRestriction

Register

SC088085

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel